TrialThe Lancet. Oncology2020

Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial.

Panagiotis A Konstantinopoulos et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.